The Future of Data in Pharma: Data Privacy, Data Ownership and Going Beyond the Pill

Posted by ZS Editors on Wed, Feb 12, 2020

Remember when big data was big news? Now all we hear about is AI, but that hasn’t made data any less relevant. Data is the fuel that feeds the business and the future of pharma, let alone AI. The world is becoming more and more data dependent while slow, tectonic shifts are under way across healthcare: There’s an increasing focus on the value of medical care over volume. The patient experience is becoming a higher priority. Data privacy and data ownership concerns are constantly threatening to upend the status quo with regulations that could be hugely disruptive.


>
Read More

The Death of Dashboards, and the Promise of Personalized Analytics

Posted by ZS Editors on Mon, Jan 07, 2019

Multiple factors are colliding to encourage the need for personalized analytics. The ever-expanding explosion of data is forcing companies to consider more nimble, automated solutions that simplify the user experience. The need for competitive advantage in a crowded marketplace is inspiring companies to arm reps with sales tools that give them an edge. Reps are increasingly expecting the kind of user experience that they get from consumer applications. The list goes on.

Personalization conjures a future where reps are no longer bombarded with information and expected to draw their own insights. In this future, AI-driven insights come to them as alerts on their mobile devices, personalized to their needs and customers, and delivered at the best possible time. 

But this is pharma. Surely the spreadsheets and dashboards will persist, right?


>
Read More

Making the Case for a New Analytics Consumption Model

Posted by ZS Editors on Thu, Nov 29, 2018

Industries like retail and technology are transitioning to an AI-driven, personalized approach to surfacing insights to end users, and they’re reaping the benefits. Life sciences companies have the same opportunity to capitalize on the runaway growth in data and rethink the way that analytics are consumed.  

ZS recently partnered with IDC to study how commercial life sciences teams are currently consuming data, and to determine their data and analytics pain points. The study revealed that sales and marketing professionals in life sciences want


>
Read More

How the Right RWE Platform Serves Up the Ingredients for Innovation

Posted by ZS Editors on Tue, Sep 04, 2018

Many pharmaceutical companies have realized the benefits of moving from standalone real-world data (RWD) projects to full-fledged, cross-functional real-world evidence (RWE) capabilities to drive everything from their R&D programs to their commercial teams’ efforts to demonstrate value—and technology is central to their success. “Real-world evidence is essentially extracting intelligence out of real-world data, and now that we have the right technology, scalable cloud storage and tremendous processing power, we’re actually able to sift through big data to find those insights,” says Abhay Jha, a principal at ZS and the business technology lead in the firm’s R&D excellence practice.  


>
Read More

DNA-Based Data Is a Hot Commodity, and Pharma Is Buying

Posted by ZS Editors on Wed, Aug 01, 2018

As the pharmaceutical industry continues along the path to precision medicine, drug discovery efforts are just one aspect of the business that increasingly will be fueled by data. A flurry of deals, including GlaxoSmithKline’s $300-million, four-year investment in 23andMe, gives us a window into how pharma companies are forming partnerships and striking deals to tap into stores of data to identify new R&D targets and fill clinical trials.


>
Read More